Literature DB >> 8837980

Reduced dopaminergic function in alcoholics is related to severe dependence.

L G Schmidt1, M Dettling, K J Graef, A Heinz, S Kuhn, J Podschus, H Rommelspacher.   

Abstract

With a view to the role of dopamine (DA) systems in reward processes and considering recent studies linking specific alleles at the DA-D2 receptor gene locus with alcoholism (especially with severe types) dopaminergic functions were evaluated in 49 alcoholics using growth hormone (GH) response to DA receptor agonist apomorphine (0.01 mg/kg subcutaneously). neuroendocrine testing was performed (during intoxication) at the time of admission to an inpatient alcohol treatment program and was repeated 7 days later (in a postintoxicated state). Patients underwent clinical examination, detoxification treatment and a subsequent rehabilitation program for abstinence including follow-up evaluation of outcome for 6 months. A two-factor analysis of variance (ANOVA) revealed a significant change of GH response (peak values corrected for baseline) over time (between intoxication and postintoxication; p < 0.001) and between abstainers and relapsers (p = 0.032). Relapse was also associated with paternal alcoholism, early onset of disease, and a more complete dependence syndrome and cerebellar atrophy. Standardized canonical discriminant coefficient was highest for reduced GH response compared to other relapse predictors in the model used. It is concluded that reduced GH response to dopaminergic stimulation corresponds to a progressed stage or syndrome of severe alcohol dependence; however, if reduced, dopaminergic function is one cause or consequence of addiction in this particular subgroup of patients that remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8837980     DOI: 10.1016/0006-3223(95)00078-X

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  7 in total

Review 1.  Exercise as a novel treatment for drug addiction: a neurobiological and stage-dependent hypothesis.

Authors:  Wendy J Lynch; Alexis B Peterson; Victoria Sanchez; Jean Abel; Mark A Smith
Journal:  Neurosci Biobehav Rev       Date:  2013-06-24       Impact factor: 8.989

2.  The ANKK1 protein associated with addictions has nuclear and cytoplasmic localization and shows a differential response of Ala239Thr to apomorphine.

Authors:  E Garrido; T Palomo; G Ponce; I García-Consuegra; M A Jiménez-Arriero; J Hoenicka
Journal:  Neurotox Res       Date:  2010-09-16       Impact factor: 3.911

3.  Association between Val66Met brain-derived neurotrophic factor (BDNF) gene polymorphism and post-treatment relapse in alcohol dependence.

Authors:  Marcin Wojnar; Kirk J Brower; Stephen Strobbe; Mark Ilgen; Halina Matsumoto; Izabela Nowosad; Elzbieta Sliwerska; Margit Burmeister
Journal:  Alcohol Clin Exp Res       Date:  2009-01-27       Impact factor: 3.455

Review 4.  Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART).

Authors:  Kenneth Blum; Thomas J H Chen; B William Downs; Abdalla Bowirrat; Roger L Waite; Eric R Braverman; Margaret Madigan; Marlene Oscar-Berman; Nicholas DiNubile; Eric Stice; John Giordano; Siobhan Morse; Mark Gold
Journal:  Postgrad Med       Date:  2009-11       Impact factor: 3.840

5.  Dopamine D2 receptors and transporters in type 1 and 2 alcoholics measured with human whole hemisphere autoradiography.

Authors:  Erkki Tupala; Håkan Hall; Kim Bergström; Tuija Mantere; Pirkko Räsänen; Terttu Särkioja; Jari Tiihonen
Journal:  Hum Brain Mapp       Date:  2003-10       Impact factor: 5.038

Review 6.  Recommended drug treatment strategies for the alcoholic patient.

Authors:  A Schaffer; C A Naranjo
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

7.  Sleep disturbance as a universal risk factor for relapse in addictions to psychoactive substances.

Authors:  Kirk J Brower; Brian E Perron
Journal:  Med Hypotheses       Date:  2009-11-11       Impact factor: 1.538

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.